Sartorius | Sartorius Stedim Biotech | January 26, 2023
Overview
Sales revenue +15%cc to €4.2bn: both divisions show double-digit growth
Underlying EBITDA +20% to €1.4bn; margin of 33.8% close to high prior-year level
Outlook 2023: low single-digit sales growth, high single-digit excluding Covid business; underlying EBITDA margin around prior-year level
Ambition 2025: fundamentally confirmed; sales revenue target increased for inflation to ~€5.5bn, margin target unchanged
Uncertainties remain high due to global geopolitical and economic situation
2
Agenda
Sartorius Group Preliminary FY 2022 results |
FY 2023 outlook | Ambition 2025
Sartorius Stedim Biotech Group Preliminary FY 2022 results |
FY 2023 outlook | Ambition 2025
Questions & Answers
3
Sartorius Group
Strong double-digit sales growth, margin close to high prior-year level
Sartorius Group
FY 2021
FY 2022
in %
in % cc1
in millions of € unless otherwise specified
Sales revenue
3,449
4,175
+21.0
+15.0
Order intake
4,268
4,007
-6.1
-10.1
Underlying EBITDA2
1,175
1,410
+20.0
Underlying EBITDA2 margin in %
34.1
33.8
-0.3pp
Underlying EPS3 (ord.) in €
8.08
9.57
+18.4
Underlying EPS3 (pref.) in €
8.09
9.58
+18.4
Strong organic sales growth; acquisitions contribute close to 2pp; Covid-related sales significantly down to ~€220m
OI reflects normalizing demand and substantially lower Covid business; excl. Covid business OI growth is slightly positive
Strong underlying EBITDA margin close to prior year despite expected catch-up of costs and slight FX-related headwinds
1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
4
Sartorius Group
High growth across all geographies; Americas expand the fastest
Americas
in millions
+21.4%
1,544
1,141
FY 2021 FY 2022
EMEA
in millions
+9.0%
1,411
1,551
FY 2021 FY 2022
Asia|Pacific
in millions
+16.2%
1,080
897
FY 2021 FY 2022
Sales by Region
in %
EMEA
Americas
~ 37%
~ 37%
€4,175m
Asia|Pacific
~ 26%
The Americas contribute most to strong sales revenue growth
Good growth in EMEA despite tough comparables; strong reduction of business in Russia
Partial lockdowns in China with no significant impact on growth in Asia|Pacific
Acc. to customers' location; growth in constant currencies
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sartorius Stedim Biotech SA published this content on 26 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 January 2023 13:52:04 UTC.
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
SARTORIUS STEDIM BIOTECH 
